Futuretech Ii Acquisition 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Futuretech Ii Acquisition in the second quarter 2025?
Due to the lack of equity, it was not possible to calculate Futuretech Ii Acquisition Corp 's return on equity (ROE) in its second quarter 2025

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter	(Sep 30 2024) III. Quarter	(Jun 30 2024) II. Quarter
Y / Y Equity Change	-	-	-	-	-
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in Millions	-2	-2	-2	1	1
Return On Equity (TTM)	-	-	-	-	-
FTII's Total Ranking	#	#	#	#	#
Equity (TTM) in Millions	-10	-9	-9	-8	-7
Seq. Equity Change	-	-	-	-	-
Seq. Net Income Change	-	-	-	-	-

Back to FTII Management Effectiveness >> FTII's 5 Years Annual ROE >> Compare FTII ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	#
Sector	#
Overall	#

Return On Equity Statistics
High	Average	Low
0 %	0 %	0 %

FTII Annual Return On Equity	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022
Total Equity in Millions	-9	-6	-3	0	0
Y / Y Equity Change	-	-	-	-	-
Net Income in Millions	-1	3	1	0	0
Y / Y Net Income Change	-	315.92 %	-	-	-
Return On Equity	-	-	-	-	-

Back to FTII Management Effectiveness >> FTII's 5 Years Annual ROE >> Compare FTII ROE to its Competitors

Annual Roe Comment

Despite deterioration in net income, company improved ROE to in 2024, company improved ROE to 315.92 % compared to the prior year.

More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
FTII's' Return on Equity at Yahoo Finance
FTII's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for FTII's Competitors
Subscribers only: Roe for Futuretech Ii Acquisition 's Suppliers
Subscribers only: Return On Equity for FTII's Customers

Companies with similar Return On Equity at Jun 30 2025, within Healthcare Sector	ROE
Nrc Health	61.35 %
Arcutis Biotherapeutics Inc	59.20 %
Illumina Inc	55.11 %
Puma Biotechnology Inc	53.09 %
Zoetis Inc	51.76 %
Concentra Group Holdings Parent Inc	50.78 %
Synlogic Inc	46.41 %
Entera Bio Ltd	46.01 %
Longduoduo Co Ltd	44.99 %
Agios Pharmaceuticals Inc	43.31 %
Tenet Healthcare Corp	42.43 %
Agilent Technologies inc	42.04 %
Edwards Lifesciences Corporation	40.93 %
Siga Technologies Inc	40.55 %
Hims and Hers Health Inc	38.17 %
Waters Corporation	34.91 %
Merck and Co Inc	34.86 %
Gilead Sciences Inc	33.08 %
Sbc Medical Group Holdings Incorporated	32.69 %
Eledon Pharmaceuticals Inc	32.28 %
Lifevantage Corp	32.06 %
Nutriband Inc	30.91 %
Acadia Pharmaceuticals Inc	30.67 %
Johnson and Johnson	30.39 %
Rafael Holdings Inc	30.38 %
Abbott Laboratories	29.77 %
Bristol myers Squibb Company	29.57 %
Prestige Consumer Healthcare Inc	28.29 %
Transmedics Group Inc	28.02 %
Catalyst Pharmaceuticals Inc	27.47 %

Date modified: 2026-09-26T07:41:43+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.